[6] Zheng ZJ, Sharrett AR, Chambless LE et al. Associations of ankle-brachial index with clinical coronary heart disease, stroke and preclinical carotid and popliteal atherosclerosis: the Atherosclerosis Risk in Communities ARIC ; study. Atherosclerosis 1997; 131: 11525. [7] Criqui MH, Denenberg JO, Langer RD, Fronek A. The epidemiology of peripheral arterial disease: importance of identifying the population at risk. Vasc Med 1997; 2: 2216. [8] Leng GC, Fowkes FG, Lee AJ, Dunbar J, Housley E, Ruckley CV. Use of ankle brachial pressure index to predict cardiovascular events and death: a cohort study. Br Med J 1996; 313: 14404. [9] Coccheri S, Palareti G, Fortunato G. Antithrombotic drugs in peripheral obliterative arterial diseases. Haemostasis 1994; 24: 11827. [10] Janzon L, Bergqvist D, Boberg J et al. Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study. J Intern Med 1990; 227: 3018. [11] CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events CAPRIE ; . Lancet 1996; 16 348 ; : 132939. [12] Collaborative overview of randomised trials of antiplatelet therapy I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 1994; 308: 81106. [13] Collaborative overview of randomised trials of antiplatelet therapy II. Maintenance of vascular graft or arterial patency by antiplatelet therapy. Antiplatelet Trialists' Collaboration. BMJ 1994; 308: 15968. [14] Girolami B, Bernardi E, Prins MH et al. Antithrombotic drugs in the primary medical management of intermittent claudication: a meta-analysis. Thromb Haemost 1999; 81: 71522. [15] Hood SC, Moher D, Barber GG. Management of intermittent claudication with pentoxifylline: meta-analysis of randomized controlled trials. CMAJ 1996; 155: 10539. [16] Reilly MP, Mohler ER. Cilostazol: treatment of intermittent claudication. Ann Pharmacother 2001; 35: 4856. [17] Dawson DL, Cutler BS, Hiatt WR et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. J Med 2000; 109: 52330. [18] Violi F, Marubini E, Coccheri S, Nenci GG. Improvement of walking distance by defibrotide in patients with intermittent claudication -- results of a randomized, placebo-controlled study the DICLIS study ; . Thromb Haemost 2000; 83: 6727. [19] Brevetti G, Diehm C, Lambert D. European multicenter study on propionyl-L-carnitine in intermittent claudication. J Coll Cardiol 1999; 34: 161824. [20] Balsano F, Coccheri S, Libretti A et al. Ticlopidine in the treatment of intermittent claudication: a 21-month doubleblind trial. J Lab Clin Med 1989; 114: 8491. [21] Palareti G, Poggi M, Torricelli P, Balestra V, Coccheri S. Long-term effects of ticlopidine on fibrinogen and haemorheology in patients with peripheral arterial disease. Thromb Res 1988; 52: 6219. [22] Andreozzi GM, Signorelli S, Cacciaguerra G et al. Threemonth therapy with calcium-heparin in comparison with ticlopidine in patients with peripheral arterial occlusive disease at Leriche-Fontaine IIb class. Angiology 1993; 44: 30713. [23] Allegra C, Pollari G, Carioti B, Sardina M. Thrombin and platelet inhibition with low dose calcium heparin in comparison with ASA in patients with peripheral arterial disease at Leriche-Fontaine IIb class. Int J Clin Pharmacol 1994; 12: 64651. [24] Palmieri G, Ambrosi G, Agrati AM, Ferraro G, Marcozzi S. A new low molecular weight heparin in the treatment of peripheral arterial disease. Int Angiol 1988; 7 3 Suppl ; : 417. [25] Mannarino E, Pasqualini L, Innocente S et al. Efficacy of low-molecular-weight heparin in the management of intermittent claudication. Angiology 1991; 42: 17.
The use of clopidogrel over alternative durations was then modelled by applying the relative risks reported in Table 26 to the baseline probabilities estimated for strategy 5 across each separate period. The RRs for clopidogrel were only applied to those periods where treatment with clopidogrel was continued. For treatment periods of less than 6 months duration strategies 3 and 4 ; , patients were assumed to revert back to the transition probabilities associated with standard care after the initial treatment period. Consequently, for strategy 4 clopidogrel for 30 days only ; , the RRs were only applied to the first 30 days; patients were then assumed to follow the same transition probabilities as standard care for the periods between 1 and 3 and 3 and 6 months. For strategy 3 clopidogrel for 3 months ; , the RRs were applied to both the first 30 days and the period between 1 and 3 months. The data at 6 months were then extrapolated to 12 months using the annual transition probabilities applied in the long-term model from the NHAR see the section `Extrapolation of 6month baseline data to 12 months', p. 39 ; . For strategy 1, the impact of continuing treatment for this additional period was modelled by also applying the RRs to these transitions. Patients in strategies 25 followed the same set of transition probabilities. The probabilities for the resource- and costgenerating ; events PTCA, CABG, fatal and nonfatal MIs, stroke and major bleeds were modelled using beta distributions for each separate period. The same unit costs as applied in the base-case model were used. The RRs for these events reported for clopidogrel were then applied to each period in which treatment with clopidogrel was continued. Table 32 presents the analysis of the ICER for this analysis. When more than two programmes are.
Pancreas transplantation is an option for some patients with complicated diabetes, most commonly patients who have had or who need a kidney transplant. Between 1995 and 2002, the number of patients receiving simultaneous pancreas and kidney transplants did not change, while the number of patients who received a pancreas transplant alone or after a kidney transplantation increased 5-fold. Solitary pancreas transplantation is controversial because of toxicity, unknown effects on secondary complications of diabetes, and no documented survival advantage. Venstrom and colleagues analyzed data from 124 approved U.S. transplantation programs from 1995 through 2000 to determine any association between solitary pancreas transplantation and survival in 11 572 patients with diabetes and preserved kidney function. They compared mortality risk among the solitary pancreas transplant recipients with the controls: Patients who were on the waiting list for the procedure. The solitary pancreas transplant recipients had a significantly increased relative risk for death at 90 days and 1 year after the procedure. After 4 years, the relative risk for death was 1.57 95% CI, 0.98 to 2.53; P 0.06 ; among the patients who received only a pancreas transplant and 1.42 CI, 1.03 to 1.94; P 0.03 ; among the patients who received a pancreas transplant after kidney transplantation. By contrast, relative risk for death was 0.43 CI, 0.39 to 0.48 ; after simultaneous transplantation of pancreas and kidney. Oneand 4-year survival rates were 96.5% and 85.2%, respectively, for the patients who received only a pancreas transplant and 95.3% and 84.5%, respectively, for the patients who received a pancreas transplant after kidney transplantation. By comparison, the corresponding survival rates for the patients on the waiting list were better: 97.6% and 92.1%, respectively, for patients waiting for a pancreas transplantation and 97.1% and 88.1%, respectively, for patients who had already received a kidney transplant. Using a multivariate analysis, Venstrom and colleagues identified recipient age, donor cause of death, enteric drainage, pancreatitis, and rejection before discharge as factors explaining post-transplantation deaths. The number of patients studied is small, and a transplantation survival advantage might require more than 4 years to become evident. The study emphasizes the importance of careful selection of patients for transplantation and suggests that better outcome in those receiving medical therapy may be due to improvements in managing brittle diabetes.
Prescription Drugs
Young kids like to see young adults who dress in nice clothes, don't do drugs, show confidence, speak appropriately and have respect for others, for instance, clopidogrel warfarin.
The results of the CHARISMA study Ckopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance ; were published in March 2006. The study was investigating whether people with major vascular risks do better with antiplatelet agents or aspirin alone. Results of the study indicated: Cloipdogrel plus aspirin was not shown to be significantly more effective than aspirin alone in reducing the incidence of MI, CVA, or death by CV disease. The rate of severe bleeding was not significantly greater with clopidogrel and aspirin than with aspirin plus placebo. The risk of moderate bleeding was significantly greater with clopidogrel and aspirin as compared to aspirin plus placebo.
16 incremental effect of clopidogrel on important outcomes in patients with cardiovascular disease : a meta-analysis of randomized trials and
cloxacillin.
Hesdorffer DC, Stables JP, Hauser WA, Annegers JF, and Cascino G. Are certain diuretics also anticonvulsants? Ann Neurol. 50: 458-62, 2001.
1102974 1188709 1224664 Cetrimonium Bromide 1 g ; Diclofenac Potassium 200 mg ; Docosyl Ferulate 50 mg ; Glyceryl Distearate 500 mg ; Heptane 1.2 mL ampule; 3 ampules ; Irbesartan 200 mg ; Oxandrolone Related Compound A CIII 20 mg ; Pentane 1.2 mL ampule; 3 ampules ; Polyoxyl 10 Oleyl Ether 1 mL ; Tizanidine Hydrochloride 200 mg ; Topiramate 200 mg ; L-Arginine 200 mg ; Butalbital CIII 200 mg ; Capreomycin Sulfate 250 mg ; Captopril Disulfide 100 mg ; Carbidopa 400 mg ; Clopid0grel Bisulfate 125 mg ; Diazepam Related Compound A 25 mg ; Diazoxide 200 mg ; Fluconazole Related Compound C 10 mg ; Furosemide 125 mg ; Gemfibrozil 200 mg ; Hydrochlorothiazide 200 mg ; Ifosfamide 500 mg ; Insulin Human 100 mg ; Megestrol Acetate 500 mg ; Mesalamine 200 mg ; Methylprednisolone Acetate 200 mg ; Nabumetone 200 mg ; Nandrolone CIII 50 mg ; Rutin 100 mg ; Salicylic Acid 125 mg ; Valsartan Related Compound C 10 mg and
cromolyn.
Aw palmetto, also known as Serenoa repens or Sabal serrulatum, is an herb that is most commonly used to treat problems related to benign prostatic hyperplasia BPH ; . The medicinal element of saw palmetto is taken from the partially dried ripe fruit of the American dwarf palm tree, which is indigenous to the coastal regions of the southern United States, from the Carolinas and Florida to California. BPH is a nearly universal result of the aging process in men. As the prostate gland enlarges, it can cause both obstructive and irritative symptoms; however, the size of the prostate gland is not predictive of the symptoms that patients experience. Saw palmetto is widely used in other countries; for example, it is used in 50 percent of treatments for BPH in Italy and in 90 percent of such treatments in Germany.1 The active part of the plant is the sterols and free fatty acids found in the berry. The particular solvent used in the extraction process affects the resulting formulation of the product. The most widely studied form of saw palmetto is Permixon, which uses the solvent hexane; other formulations have used ethanol, methanol, and liquid carbon dioxide as solvents. Historically, saw palmetto was administered with nettle root and pumpkin seeds, and some modern formulations include these elements. It is unclear which components are the most active, and the mechanism of action is.
Further glucuronidation results in urinary excretion of the parent drug and its metabolites and danocrine.
Mon defective alleles will predict the CYP2D6 phenotype with about 95-99% certainty18, 51. For example, the most common CYP2D6 variant alleles in the, Caucasian52, Chinese Japanese53 and Black African Afro-American18 population are CYP2D6 * 4, * 10 and * 17 respectively. ETHNIC ASPECTS Racial and ethnic studies of drug metabolism have shown substantial inter-population differences in the polymorphic distribution of CYP2D6 activity and corresponding genetic materials. The prevalence of and UEM in different ethnic groups is shown in Table 3 and 4. This polymorphism has been extensively studied in Caucasians and Orientals with results consistently showing a prevalence of PMs of 5-10% in.
A second larger study was conducted in 1250 hospitals in China and co-ordinated by the Clinical Trials Service Unit at the University of Oxford. This study enrolled 45, 852 patients who presented within 24 hours of the onset of symptoms of suspected acute MI with STsegment elevation or depression or left BBB. Patients were randomised in a 2 factorial design to receive clopidogrel 75mg daily ; or placebo and metoprolol or placebo for up to 4 weeks in hospital or death or hospital discharge whichever came first. All patients received aspirin 162mg daily ; . This design allowed separate assessment of the effects of clopidogrel and metoprolol. Results are presented for the clopidogrel analysis only. There were two coprimary endpoints: 1 ; the composite of death, reinfarction or stroke and 2 ; death from any cause until hospital discharge or 28 days whichever came first. The mean study treatment duration in survivors in both treatment groups was 15 days. The composite primary endpoint of death, reinfarction or stroke occurred in 9.2% 2, 121 ; cl9pidogrel patients and 10% 2, 310 ; in placebo patients, representing a 9% relative risk reduction 95% CI: 3%, 14%, p 0.002 ; . Death from any cause was reported in 7.5% 1, 726 ; cloopidogrel and 8.1% 1, 845 ; placebo patients; representing a 7% relative risk reduction 95% CI: 1%, 13%, p 0.03 ; . Patients treated with clopidogrfl had a lower rate of fatal and non-fatal re-infarction 2.1% versus 2.4% in the placebo group representing a 14% relative risk reduction 95% CI: 3%, 24%, p 0.02 ; . However, there was no significant difference in the incidence of any type of stroke between the groups 0.9% versus 1.1% respectively, p 0.11 and ddavp.
Buy cheap Clopidogrel
Chartered health plan was overpaid $1 5 million, and health right was paid $ 1 million in excess.
11.1.4 OTHER DRUGS FOR ARTHRITIS $ X supartz !!!! EUFLEXXA !!!!! HYALGAN !!!!! ORTHOVISC !!!!! SYNVISC X 11.2 DRUGS TO PREVENT AND TREAT GOUT $ X allopurinol $ X colchicine $ X probenecid 11.3.1 DIRECT MUSCLE RELAXANTS $ X baclofen $ X tizanidine hcl 11.3.2 CNS MUSCLE RELAXANTS $ X carisoprodol $ X cyclobenzaprine hcl $ X methocarbamol $ X orphenadrine citrate $ X orphenadrine citrate INJ ; $$$$$ SKELAXIN CHAPTER 12: NUTRITION, BLOOD 12.1.2 VITAMINS & MINERALS & RELATED PRODUCTS $$ FOLTX X $$ METANX $$$ CEREFOLIN 12.1.3 THERAPEUTIC VITAMINS & MINERALS $ X calcitriol $ X folic acid $$$ PHOSLO X !!!!! HECTOROL X 12.2 POTASSIUM SUPPLEMENTS $ X klor-con $ X potassium chloride 12.3.1 ORAL ANTICOAGULANTS, VITAMIN K $ X warfarin sodium $$ COUMADIN X 12.3.2 HEPARIN AND HEPARIN ANTAGONISTS ARIXTRA PA FRAGMIN PA X INNOHEP PA LOVENOX PA X 12.4 ANTIPLATELET DRUGS $ X cilostazol $ X clopidogrel bisulfate and
stimate.
So this is fairly common: people trained in public health and people who like to write papers like to do meta-analysis because you don't really have to collect any of your own data, for instance, clopidogrel bisulfate 75 mg.
Wienen W., Cardiovasc Drug Rev 2000; 18: 127-156 Neutel JM., Adv Ther 1998; 15: 206-217 and
desmopressin.
HIV CKR-5 Gene, DNA Mutation Analysis HIV-1 Antibody Screen with Reflex to Western Blot Confirmation HIV-1 Antibody, Western Blot HIV-1 DNA, Qualitative PCR3 HIV-1 Genotype2 HIV-1 Genotype with Graphical Report HIV-1 gp41 Envelope Genotype2 HIV-1 Genotype and Phenotype, PhenoSenseTM GTTM V7000 & V7100 ; HIV-1 Phenotype, PhenoSenseTM HIV Comprehensive V3200 ; HIV-1 Phenotype, Antivirogram HIV-1 RNA Quantitative PCR, Ultrasensitive HIV-1 RNA Quantitative PCR with Reflex to Genotype2 HIV-1 RNA, Quantitative bDNA v3.0 ; HIV-1 RNA, Quantitative bDNA with Reflex to HIV-1 Genotype2 HIV-1 RNA, Quantitative bDNA with Reflex to VirtualPhenotypeTM2 HIV-1 RNA, Quantitative PCR HIV-1 RNA, Quantitative PCR, Expanded Range HIV-1 RNA, Quantitative PCR with Reflex to VirtualPhenotype2 HIV-1 VirtualPhenotype for Drug Resistance to PRI and RTI2 HIV-1 Western Blot with Reflexes to HIV-2 Screen and Western Blot HIV-1 HIV-2 Antibodies, Western Blot1 HIV-1 HIV-2 Antibody, EIA with Positives Reflexed to HIV-1 Western Blot HIV-1 HIV-2 Antibody, EIA, with Reflex es ; to Western Blot HIV-2 Antibody, EIA, with Positives Reflexed to Western Blot HIV-2 Antibody, Western Blot1 Immunization Immunity Diphtheria Antitoxoid Antibody2 Diphtheria Antitoxoid, Titer to Endpoint2 Diphtheria Antitoxoid, Pre and Post2 Diphtheria Antitoxoid & Tetanus Antitoxoid Antibodies Hepatitis A Total Antibody, Immune Status Hepatitis B Immunity Screen Measles Antibody IgG ; Measles Antibodies IgG, IgM ; Measles, Mumps, and Rubella Antibodies IgG ; Mumps Virus Antibody IgG ; Mumps Virus Antibodies IgG, IgM ; Pneumococcal Antibody Prevnar Vaccine Response ; Rubella Immune Status Rubella IgG Antibody ; Rubella Antibody IgM ; Rubella Antibodies IgG, IgM ; Tetanus Antitoxoid Antibody EIA ; 2 Torch Panel IgG & IgM, for example, clopidogrel order.
District Court Judge William G. Young found: This has been a gross abuse of the Medicare Medicaid repayment system, knowing, intelligent. You have demonstrated, and it's all been confirmed in open court, and I don't want anyone forgetting about the fact that this company, not under its present management, knowingly abused the public trust in a most, and I use my words carefully, despicable way. United States v. TAP Pharmaceutical Products, Inc., No. CR-01-10354-WGY D. Mass, Dec. 6, 2001 ; . 3. 157. The Defendant Drug Manufacturers' Fraudulent Conduct Within the Medicare Part B Program The Defendant Drug Manufacturers each perpetrated the alleged fraudulent and decadron.
8. Have you had any of the abdominal surgeries listed below: Cholecystectomy removal of the gallbladder ; Hysterectomy removal of the uterus ; C-section Other not listed please describe briefly ; MEDICATIONS YOU CURRENTLY TAKE AND PAST MEDICAL HISTORY 9. List all the medications you have been taking within the last month including the ones taken on "as needed" basis ; : 10. Specifically, within the last month did you at least once take any of the following medications: Aspirin, Ibuprofen, Advil, Naprosyn, Voltaren, or similar anti-inflamatory medications Coumadin Warfarin ; Plavix Coopidogrel ; Heparin Ticlid Ticlopidine ; Lovenox Enoxaparin.
[Photo: : corr ate.id our facilities locations ] A Caldwell woman who was badly burned while cooking meth in her kitchen a few years ago spoke about her struggle."I just took it 1 time and I was hooked ; , " said Shelley Odlum. "It can happen to anyone." She showed photos of burns and skin grafts the end of an 8-year whirlwind of drug use that [endangered her family]. She has been clean 2 years and speaks at high schools about meth dangers. "Our lives are started over and it is wonderful. It's funny how everything falls into place if you can just get away from it." Idaho's prison population is at an all-time high, Beauclair said: 6, 631 inmates are incarcerated, and those on probation and parole number over 11, 000. The department might have to send inmates out of state by year's end with facilities are at or above capacity. "The common thread is meth and the destruction it's done to this community, " said Rich Hammond, Dist. 3 Probation Parole manager and dexamethasone.
Clopidogrel pharmacy
Decreased by 6.4% 95% CI, 4.6% to 16.3% ; and absolute risk decreased by 1% CI, 0.6% to 2.7% ; . However, the risk for life-threatening hemorrhage was significantly increased in the group receiving combination therapy compared with the group receiving clopidogrel therapy alone 96 [2.6%] vs. 49 [1.3%]; absolute risk increase, 1.3 percentage points [CI, 0.6 to 1.9 percentage points] ; . In conclusion, combination therapy with clopidogrel and aspirin provided no benefit over clopidogrel alone in the secondary prevention of vascular events in patients with a recent ischemic stroke or transient ischemic attack and 1 additional vascular risk factor ; and increased the risk for serious bleeding. As a result, dual antiplatelet regimens with clopidogrel and aspirin can no longer be recommended as an option for secondary preventive therapy in this patient population.
These groups of medicines are used as symptomatic treatment specifically for mood changes and
divalproex and
clopidogrel, because clarity clopidogrel.
Events versus aspirin which will prevent 19 events per 1000 patients treated per year. The cost impact of preventing 5 additional events with clopidogrel therapy needs to be elucidated in order to determine the relative worth of introducing this novel anti-platelet for use in the clinical setting amongst other pharrnacological agents.
Importantly, in a 2005 paper in jacc, credo investigators reported that platelet inhibition with clopidogrel loading before pci followed by therapy for 1 year is highly cost effective and tolterodine.
Produced by Authors Centre for Reviews and Dissemination, Centre for Health Economics, University of York King, Sarah, Dr, Research Fellow, Centre for Reviews and Dissemination Griffin, Susan, Ms, Research Fellow, Centre for Health Economics Hodges, Zo, Ms, Research Fellow, Centre for Reviews and Dissemination Weatherly, Helen, Ms, Research Fellow, Centre for Health Economics Asseburg, Christian, Mr, Research Fellow, Centre for Health Economics Richardson, Gerry, Mr, Research Fellow, Centre for Health Economics Golder, Su, Ms, Information Officer, Centre for Reviews and Dissemination Taylor, Eric, Prof, Child and Adolescent Psychiatry, Institute of Psychiatry, Kings College London Drummond, Mike, Prof, Professor of Health Economics, Centre for Health Economics Riemsma, Rob, Dr, Senior Research Fellow, Centre for Reviews and Dissemination Correspondence to Dr Sarah King Centre for Reviews and Dissemination, University of York, York, YO10 5DD Tel: 01904 ; 321062, Fax: 01904 ; 321041 E-mail: sek3 york.ac Date completed Expiry date 9 December, 2004 December, 2006.
Clinical trials There have been only two prospective randomized studies of the treatment of patients with ET. In the first, 114 highrisk patients age 60 years or prior thrombosis ; were randomized to receive hydroxyurea or no cytoreductive agent.20 Patients with a platelet count 1500 109 L were excluded. During a median follow up period of 27 months, patients on hydroxyurea developed significantly fewer thrombotic events P 0.003 ; . This was the first clear demonstration that cytoreductive therapy reduces thrombotic events in patients with ET. The second randomized study was the Medical Research Council MRC ; primary thombocythemia-1 PT-1 ; trial, 2 in which high-risk patients prior thrombosis, age 60 years or platelets 1000 109 L ; were randomized to receive hydroxyurea plus aspirin or anagrelide plus aspirin. With over 800 patients randomized and with central clinical and histological review of end-points, it is the largest.
Every time a behavioral restraint is applied the following information should be documented: circumstances surrounding the use alternatives that were considered or failed rationale for using that particular type of restraint notification of the family if consent was obtained by your patient and the family agreed to be notified communication to your patient explaining the behavior criteria for restraint discontinuation assistance provided to your patient to help him or her meet the behavior criteria for restraint discontinuation every in-person evaluation and re-evaluation of your patient methods of how the continuous monitoring occurred assessments of your patient every 15 minutes debriefing that occurred with your patient and staff after the restraint was discontinued jcaho, 2007 ; every time a medical surgical restraint is used, you must document: relevant orders for use of the restraints results of your patient monitoring as described previously ; reassessment at two hour intervals minimum ; significant changes in your patient's condition when restraint is used as part of a protocol, your patient's chart must contain a reference to the particular protocol.
1. American Heart Association. Heart disease and stroke statistic--2004 update. Report available online at: : americanheart downloadable heart 19-04 . 2004. 2. Rosenberg C, Popelka GM. Post-stroke rehabilitation. A review of guidelines for patient management. Geriatrics 2000; 55: 75 Spagnoli LG, Mauriello A, Sangiorgi G, et al. Extracranial thrombotically active carotid plaque as a risk factor for ischemic stroke. JAMA 2004; 292: 184552. Vickrey BG, Rector TS, Wickstrom SL, et al. Occurrence of secondary ischemic events among persons with atherosclerotic vascular disease. Stroke 2002; 33: 901 CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events CAPRIE ; . Lancet 1996; 348: 1329 Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study. 2. Dipyramidole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143: 113. Hardie K, Hankey GJ, Jamrozik K, Broadhurst RJ, Anderson C. Ten-year survival after first stroke in the Perth community stroke study. Stroke 2003; 34: 1842 Gorelick PB. Stroke prevention. Arch Neurol 1995; 52: 34755. Volpato S, Maraldi C, Ble A, et al. Prescription on antithrombotic therapy in older patients hospitalised for transient ischemic attack and ischemic stroke: the GIFA study. Stroke 2004; 35: 9137. Holloway RG, Benesch C, Rush SR. Stroke prevention: narrowing the evidence-practice gap. Neurology 2000; 54: 1899 Arora S, Broderick SP, Frankel M, et al. Acute stroke care in the US: results from 4 pilot prototypes of the Paul Coverdell National Acute Stroke Registry. Stroke 2005; 36: 1232 Ovbiagele B, Saver JL, Fredieu A, et al. PROTECT: a coordinated stroke treatment program to prevent recurrent thromboembolic events. Neurology 2004; 63: 121722. Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992; 326: 381 Ness J, Aronow WS. Prevalence of coexistence of coronary artery disease, ischemic stroke, and peripheral arterial disease in older persons, mean age 80 years, in an academic hospital-based geriatrics practice. J Geriatr Soc 1999; 47: 1255.
Clopidogrel tablets
